November 2025 saw pivotal FDA approvals, including durvalumab for gastric cancers and pembrolizumab/enfortumab vedotin for ...

Three months ago, fishers found loggerhead sea turtle Molly with a 10-lb. tumor on her neck. Now, Molly is on the mend and ...

It's not often that a pathologist gets to make a diagnosis that works for the patient by preventing treatment from occurring.

Researchers focused on accelerating and testing new treatments for low-grade brain tumors are set to receive a transformative £2.8 million to drive their future work.

Profound would also like to congratulate Satoru Takahashi, MD, PhD, of Takatsuki General Hospital in Japan, for receiving a Certificate of Merit award from RSNA for his presentation titled “TULSA for ...

In November 2025, the U.S. Food and Drug Administration (FDA) issued several approvals across oncology and supportive care.

It's not surprising that pancreatic cancer is often referred to as a silent killer. With few early symptoms and an aggressive ...

As the first immunotherapy option in this setting, the approval sets a new standard for resectable early-stage gastric and gastroesophageal junction (GEJ) cancers.